EVC
DMAC icon

Eidelman Virant Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Eidelman Virant Capital’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-35,000
Closed -$173K – 122
2019
Q2 		$173K Buy
+35,000
New +$121K 0.09% 109

Other funds holding DMAC

MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Eidelman Virant Capital's DMAC Position: Q3 2019 in Review

Eidelman Virant Capital sold out of DiaMedica Therapeutics (DMAC) in Q3 2019, closing a stake of 35,000 shares — an estimated $173K sold.

Eidelman Virant Capital first reported a position in DMAC in Q2 2019 and held it in 1 quarter. The position peaked at $173K in Q2 2019. 17 funds tracked by Wall St. Rank hold DMAC as of Q3 2019.

  • Eidelman Virant Capital reported no remaining DiaMedica Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Eidelman Virant Capital sold 35,000 DiaMedica Therapeutics shares in Q3 2019, an estimated $173K.
  • Eidelman Virant Capital first reported a position in DiaMedica Therapeutics in Q2 2019 and held it in 1 quarter.
  • Eidelman Virant Capital's DiaMedica Therapeutics position peaked at $173K in Q2 2019.
  • 17 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2019.

Based on Eidelman Virant Capital's 13F filing for Q3 2019, filed 29 Oct 2019.